BALICATIB

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII E00MVC7O57
EPA CompTox DTXSID10188989

Structure

InChI Key LLCRBOWRJOUJAE-UHFFFAOYSA-N
Smiles CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1
InChI
InChI=1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29)

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H33N5O2
Molecular Weight 411.55
AlogP 2.29
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 7.0
Polar Surface Area 88.47
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 30.0

Bioactivity

Mechanism of Action Action Reference
Cathepsin K inhibitor INHIBITOR PubMed
Protein: Cathepsin K
Description: Cathepsin K
Organism : Homo sapiens
P43235 ENSG00000143387
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Protease Aspartic protease Aspartic protease AA clan Aspartic protease A1A subfamily
- - - 1 -
Enzyme Protease Cysteine protease Cysteine protease CA clan Cysteine protease C1A family
- 1-5 - 28000-65000 -
Assay Description Organism Bioactivity Reference
Inhibitory constant against rabbit cathepsin K using Z-Phe-Arg-AMC substrate Oryctolagus cuniculus 1.4 nM
Inhibitory activity against humanized rabbit cathepsin K Oryctolagus cuniculus 1.4 nM
Inhibitory activity against human cathepsin B expressed in HepG2 cells Homo sapiens 61.0 nM
Inhibitory activity against human cathepsin L Homo sapiens 503.0 nM
Inhibitory activity against human cathepsin L expressed in HepG2 cells Homo sapiens 48.0 nM
Inhibitory activity against rabbit cathepsin K Oryctolagus cuniculus 2.7 nM
Effect of compound on degradation of collagen in osteoclast bone resorption assay Oryctolagus cuniculus 97.0 nM
Inhibitory activity against mouse cathepsin S in mouse splenocytes Mus musculus 480.0 nM
Inhibition of human cathepsin K Homo sapiens 0.6 nM
Inhibition of rabbit cathepsin K Oryctolagus cuniculus 2.7 nM
Inhibition of bone resorption in rabbit osteoclast Oryctolagus cuniculus 97.0 nM
Inhibition of cathepsin B in human HepG2 cells None 61.0 nM
Inhibition of cathepsin L in human HepG2 cells None 48.0 nM
Antiosteoporotic activity in postmenopausal woman with osteoporosis assessed as decrease in bone resorption-associated serum CTX-1 level at 50 mg/kg Homo sapiens 61.0 %
Antiosteoporotic activity in postmenopausal woman with osteoporosis assessed as decrease in bone resorption-associated urinary CTX-1 level at 50 mg/kg Homo sapiens 55.0 %
Inhibition of cathepsin K None 1.4 nM
Inhibition of human recombinant CatK assessed as suppression of enzyme-mediated Z-Phe-Arg-AMC cleavage incubated for 1 hrs by QFRET assay Homo sapiens 5.0 nM
Inhibition of osteoclastogenesis in human bone marrow-derived stem cells assessed as reduction of pit formation by measuring TRACP5b activity after 7 days by bone TRAP assay Homo sapiens 26.6 nM
Inhibition of cathepsin-k None 5.0 nM
Inhibition of human cathepsin K using Z-Leu-Arg-AMC fluorogenic substrate incubated for 60 mins Homo sapiens 1.29 nM
Inhibition of human cathepsin-K using Z-Gly-Pro-Arg-AMC as substrate preincubated for 30 mins measured after 10 mins by fluorescence assay Homo sapiens 1.4 nM
Inhibition of human cathepsin-L using Z-Phe-Arg-AMC as substrate preincubated for 30 mins measured after 10 mins by fluorescence assay Homo sapiens 503.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 2.33 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 22.03 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 21.85 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.86 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.55 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.55 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.86 %

Cross References

Resources Reference
ChEMBL CHEMBL371064
DrugBank DB12239
FDA SRS E00MVC7O57
Guide to Pharmacology 7861
PubChem 10201696
SureChEMBL SCHEMBL1587772
ZINC ZINC000003954923
CONTENTS